Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

280 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and efficacy of jaktinib (a novel JAK inhibitor) in patients with myelofibrosis who are relapsed or refractory to ruxolitinib: A single-arm, open-label, phase 2, multicenter study.
Zhang Y, Zhang Q, Liu Q, Dang H, Gao S, Wang W, Zhou H, Chen Y, Ma L, Wang J, Yang H, Lu B, Yin H, Wu L, Suo S, Zhao Q, Tong H, Jin J. Zhang Y, et al. Among authors: suo s. Am J Hematol. 2023 Oct;98(10):1579-1587. doi: 10.1002/ajh.27031. Epub 2023 Jul 19. Am J Hematol. 2023. PMID: 37466271 Free article. Clinical Trial.
[Efficacy and safety analysis of different dose idarubicin plus cytarabine regimen as induction chemotherapy for young patients with de-novo acute myeloid leukemia].
Zhang Y, Yao XM, Zhu SL, Suo SS, Mao LP, Wei JY, Yu WJ, Mai WY, Tong HY, Meng HT, Qian WB, Jin J. Zhang Y, et al. Among authors: suo ss. Zhonghua Xue Ye Xue Za Zhi. 2016 Aug 14;37(8):682-7. doi: 10.3760/cma.j.issn.0253-2727.2016.08.010. Zhonghua Xue Ye Xue Za Zhi. 2016. PMID: 27587250 Free PMC article. Clinical Trial. Chinese.
Improved long-term survival in all Sanz risk patients of newly diagnosed acute promyelocytic leukemia treated with a combination of retinoic acid and arsenic trioxide-based front-line therapy.
Lou Y, Lu Y, Zhu Z, Ma Y, Suo S, Wang Y, Chen D, Tong H, Qian W, Meng H, Mai W, Yu W, Xu W, Wang L, Mao L, Pei R, Jin J. Lou Y, et al. Among authors: suo s. Hematol Oncol. 2018 Jun 3. doi: 10.1002/hon.2519. Online ahead of print. Hematol Oncol. 2018. PMID: 29862538
280 results